When governments have to weigh public health against IP issues, LDCs and developing countries really have no choice but to…
Two reports, released in early June, have both good news and bad news for the pharma industry in India
Just as 2015 is a make or break year for PM Modi, this will be a decisive year for the…
India once again made it to the Priority Watch list of the 2015 USTR Special 301 Report, but this year,…
As Prime Minister Modi completes a year in office this May, there will no doubt be many lists of this…
As we settle into FY2016, it is worth taking a quick look at some of the earning previews of the…
Success hinges on the company getting its GMP right and surviving the glare of regulatory scrutiny
Finance Minister Arun Jaitley’s first Union Budget had nothing special for the pharmaceutical industry
As in previous years, we mark this Women’s Day with a cover story section devoted to women’s health issue
The draft National IPR policy, unveiled last December by the Department of Industrial Policy & Promotion (DIPP), has already garnered…
While we are urged to look beyond the sticky issues, one cannot overlook the final impact of decisions on India’s…
CDSCO’s planned ‘harmonisation of recruitment rules’ is sure to resurrect this debate
Loading…
Something went wrong. Please refresh the page and/or try again.